Abstract:Abstract Background: Nanoparticles for over forty years have been the subject of a large number of physical and bioscience research . In the last decade use of these particles in medicine has gone from theoretical to clinical trials. Passive targeting of metal-based nanoparticles takes advantage of inherent abnormalities in tumor vasculature allowing accumulation in solid tumors through a process known as the ‘‘enhanced permeability and retention’’ (EPR) effect. In animal tumor implant models, combination of gold and silicone nanoparticle (GSN) and exposure of tumors to laser light (at 808nm) generated enough heat to cause tumor cell death. Mast cell tumors (MCT) are the most common skin tumor in dogs, with an estimate of MCT being roughly 20% of canine skin tumors. The goal of this pilot study is to evaluate nanoparticle and laser tumor thermal ablation on low grade canine MCT model. Results: 38 dogs with 44 mast cell tumors were enrolled in this prospective pilot study. All control tumors and those biopsied prior to laser therapy were found to be low grade MCT by histopathology (two grade method). After random number generation 8 dogs were assigned to control group and 30 dogs were assigned to treatment group. Treatment group had 36 total tumors and control group had 8 tumors present at time of enrollment. Treatment dogs had a 100% response rate, with 94% achieving clinical remission (34 tumors). Recurrence rate was 17% in those tumors achieving clinical remission. Mean progression free time (PFT) for the treatment group was 552 days and mean PFT for the control group was 1095 days. Conclusion: In conclusion results of this study suggest that photothermal ablation using gold-silicone nanoparticles and exposure to near infrared light (808 nm) provides an effective local therapy of low-grade mast cell tumors. Median progression free time and survival was not reached in our treatment group. Suggesting that long term tumor control is possible with PTA that potentially equals surgery when margins are narrow (<0.3cm) or incomplete. PTA appears to have better and more durable MCT responses than either radiation therapy and electrochemotherapy when used as sole therapies.

Reassigned surgical margins after neoadjuvant chemotherapy results in low local recurrence in dogs with mast cell tumours

Tumor Grade and Mitotic Count Are Prognostic for Dogs with Cutaneous Mast Cell Tumors Treated with Surgery and Adjuvant or Neoadjuvant Vinblastine Chemotherapy

Subcutaneous mast cell tumours: A prospective multi-institutional clinicopathological and prognostic study of 43 dogs

Investigation of efficacy of two different chemotherapy protocols used in neoadjuvant chemotherapy in clinical stages II-IV canine malignant mammary tumours

The Use of Sentinel Lymph Node Mapping for Canine Mast Cell Tumors

Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4‐DNA electrovaccination: A retrospective study on 155 cases

Oxidative Status and Lipid Metabolism Analytes in Dogs with Mast Cell Tumors: A Preliminary Study

Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy

Locoregional recurrence and survival of breast−conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate

Intensive Multimodal Chemotherapy in a Dog Suffering from Grade III/Stage IV Solid Mammary Carcinoma

A Pilot Study Using Nanoparticles and Laser Induced Photothermal Ablation to Treat Low Grade Canine Mast Cell Tumors: Evaluation of Efficacy and Safety

Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis

Perineural invasion as a predictor of local recurrence in cats with squamous cell carcinoma treated with electrochemotherapy

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Effects of Electrochemotherapy with Cisplatin and Peritumoral IL-12 Gene Electrotransfer on Canine Mast Cell Tumors: a Histopathologic and Immunohistochemical Study

An Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1

Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy

Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer

Recurrence/prognosis estimation using a molecularly positive surgical margin‐based model calls for alternative curative strategies in pIIIA/N2 NSCLC

Association of Systemic Inflammatory and Immune Indices With Survival in Canine Patients With Oral Melanoma, Treated With Experimental Immunotherapy Alone or Experimental Immunotherapy Plus Metronomic Chemotherapy